| 1. |
|
|
| 2. |
- Boulo, S., et al.
(författare)
-
First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays
- 2020
-
Ingår i: Alzheimer's and Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 16:11, s. 1493-1503
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Reference materials based on human cerebrospinal fluid were certified for the mass concentration of amyloid beta (Aβ)1-42 (Aβ42). They are intended to be used to calibrate diagnostic assays for Aβ42. Methods: The three certified reference materials (CRMs), ERM-DA480/IFCC, ERM-DA481/IFCC and ERM-DA482/IFCC, were prepared at three concentration levels and characterized using isotope dilution mass spectrometry methods. Roche, EUROIMMUN, and Fujirebio used the three CRMs to re-calibrate their immunoassays. Results: The certified Aβ42 mass concentrations in ERM-DA480/IFCC, ERM-DA481/IFCC, and ERM-DA482/IFCC are 0.45, 0.72, and 1.22μg/L, respectively, with expanded uncertainties (k=2) of 0.07, 0.11, and 0.18μg/L, respectively. Before re-calibration, a good correlation (Pearson's r>0.97), yet large biases, were observed between results from different commercial assays. After re-calibration the between-assay bias was reduced to<5%. Discussion: The Aβ42 CRMs can ensure the equivalence of results between methods and across platforms for the measurement of Aβ42. © 2020 the Alzheimer's Association
|
|
| 3. |
- Andreasson, Ulf, 1968, et al.
(författare)
-
Commutability of the certified reference materials for the standardization of beta-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and beta-amyloid 1-40 measurements
- 2018
-
Ingår i: Clinical Chemistry and Laboratory Medicine. - : Walter de Gruyter GmbH. - 1434-6621 .- 1437-4331. ; 56:12, s. 2058-2066
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The core Alzheimer's disease cerebrospinal fluid (CSF) biomarkers total tau (T-tau), phosphorylated tau (P-tau), beta-amyloid 1-42 (A beta 42) and beta-amyloid 1-40 (A beta 40) are increasing in importance and are now part of the research criteria for the diagnosis of the disease. The main aim of this study is to evaluate whether a set of certified reference materials (CRMs) are commutable for A beta 42 and to serve as a feasibility study for the other markers. This property is a prerequisite for the establishment of CRMs which will then be used by manufacturers to calibrate their assays against. Once the preanalytical factors have been standardized and proper selection criteria are available for subject cohorts this harmonization between methods will allow for universal cut-offs to be determined. Methods: Thirty-four individual CSF samples and three different CRMs where analyzed for T-tau, P-tau, A beta 42 and A beta 40, using up to seven different commercially available methods. For A beta 40 and A beta 42 a mass spectrometry-based procedure was also employed. Results: There were strong pairwise correlations between the different methods (Spearman's p>0.92) for all investigated analytes and the CRMs were not distinguishable from the individual samples. Conclusions: This study shows that the CRMs are commutable for the different assays for A beta 42. For the other analytes the results show that it would be feasible to also produce CRMs for these. However, additional studies are needed as the concentration interval for the CRMs were selected based on A beta 42 concentrations only and did in general not cover satisfactory large concentration intervals for the other analytes.
|
|
| 4. |
- Hillberg, Emil, et al.
(författare)
-
Flexibility to support the future power systems
- 2019
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- Power system flexibility relates to the ability of the power system to manage changes. Solutions providing advances in flexibility are of utmost importance for the future power system. Development and deployment of innovative technologies, communication and monitoring possibilities, as well as increased interaction and information exchange, are enablers to provide holistic flexibility solutions. Furthermore, development of new methods for market design and analysis, as well as methods and procedures related to system planning and operation, will be required to utilise available flexibility to provide most value to society. However, flexibility is not a unified term and is lacking a commonly accepted definition. The flexibility term is used as an umbrella covering various needs and aspects in the power system. This situation makes it highly complex to discuss flexibility in the power system and craves for differentiation to enhance clarity. In this report, the solution has been to differentiate the flexibility term on needs, and to categorise flexibility needs in four categories: Flexibility for Power, Flexibility for Energy, Flexibility for Transfer Capacity, and Flexibility for Voltage. Here, flexibility needs are considered from over-all system perspectives (stability, frequency and energy supply) and from more local perspectives (transfer capacities, voltage and power quality). With flexibility support considered for both operation and planning of the power system, it is required in a timescale from fractions of a second (e.g. stability and frequency support) to minutes and hours (e.g. thermal loadings and generation dispatch) to months and years (e.g. planning for seasonal adequacy and planning of new investments). The categorisation presented in this report supports an increased understanding of the flexibility needs, to be able to identify and select the most suitable flexibility solutions.
|
|
| 5. |
|
|
| 6. |
- Rönnelid, Johan, et al.
(författare)
-
The European Consensus Finding Study Group (ECFSG) Helps Characterizing New Tentative Reference Standards For Autoantibody Measurement
- 2017
-
Ingår i: Annals of the Rheumatic Diseases. - : BMJ Publishing Group Ltd and European League Against Rheumatism. - 0003-4967 .- 1468-2060. ; 76, s. 461-461
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Since 1988, the European Consensus Finding Study Group on autoantibodies in rheumatic diseases (ECFSG), also known as the EULAR autoantibody study group, has been distributing sera with unspecified antibodies to European laboratories (presently n=43) for evaluation of different autoantibody measurement techniques in a clinical context. Use of reference materials helps to align test results by adopting internationally used measurement units, but reference materials are missing for many autoantibody specificities.
|
|
| 7. |
|
|
